SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Precise Angiogenesis and Immune Modulation Research

Executive Summary: SU5416 (Semaxanib) is a highly selective small molecule inhibitor of VEGFR2 (Flk-1/KDR) tyrosine kinase, effectively suppressing VEGF-induced angiogenesis in vitro and in vivo (APExBIO). It also functions as an aryl hydrocarbon receptor (AHR) agonist, modulating immune responses through IDO induction and Treg differentiation. The compound displays a low IC50 (0.04±0.02 μM) for VEGF-driven mitogenesis inhibition in HUVEC cells, and achieves significant tumor growth suppression in mouse xenograft models at 1–25 mg/kg intraperitoneal dosing (no mortality reported). SU5416 is insoluble in water and ethanol but dissolves at ≥11.9 mg/mL in DMSO, facilitating versatile experimental protocols. These properties make SU5416 a gold-standard tool for dissecting angiogenic and immunomodulatory mechanisms in cancer and vascular biology (Xiao et al., 2024).

Biological Rationale

Angiogenesis is a hallmark of tumor progression and chronic inflammation. Vascular endothelial growth factor (VEGF) signaling, mediated mainly via VEGFR2 (Flk-1/KDR), governs endothelial cell proliferation, migration, and new blood vessel formation (Xiao et al., 2024). Aberrant VEGF pathway activation supports tumor vascularization, facilitating nutrient delivery and metastasis. Inhibiting VEGFR2 disrupts this process, offering a targeted strategy for anti-angiogenic therapy. Regulation of immune tolerance and modulation of the tumor microenvironment are also tightly linked to angiogenic signaling and AHR-mediated metabolic pathways. SU5416 (Semaxanib) enables researchers to dissect these intersecting networks at molecular, cellular, and organismal levels (APExBIO).

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 inhibitor

SU5416 is a competitive, ATP-mimetic inhibitor targeting the kinase domain of VEGFR2 (Flk-1/KDR). It blocks VEGF-induced autophosphorylation of VEGFR2, inhibiting downstream signaling cascades (including PI3K/AKT and MAPK pathways) essential for endothelial cell proliferation, migration, and permeability. This inhibition suppresses the formation of new blood vessels in both physiological and pathological contexts. SU5416 also acts as a potent agonist of the aryl hydrocarbon receptor (AHR). Upon activation, AHR translocates to the nucleus, upregulates indoleamine 2,3-dioxygenase (IDO), and promotes regulatory T cell (Treg) differentiation. These effects contribute to immune suppression and tolerance, with implications for autoimmune disease models and transplant biology (Xiao et al., 2024; APExBIO).

Evidence & Benchmarks

• SU5416 inhibits VEGF-induced mitogenesis in human umbilical vein endothelial cells (HUVECs) with an IC50 of 0.04±0.02 μM, under standard cell culture conditions (37°C, 5% CO₂, serum-free medium) (APExBIO).
• Daily intraperitoneal administration of 1–25 mg/kg SU5416 in mouse xenograft models significantly reduces tumor growth, with no reported mortality at higher doses (4–6 weeks, immunodeficient mice) (APExBIO).
• SU5416 blocks VEGFR2 phosphorylation and downstream PI3K/AKT activation in primary vascular cells, observed by immunoblotting and functional proliferation assays (Xiao et al., 2024).
• As an AHR agonist, SU5416 induces IDO expression and enhances Treg differentiation in vitro, supporting immune tolerance in preclinical transplant and autoimmune models (Xiao et al., 2024).
• Optimal solubility of SU5416 is ≥11.9 mg/mL in DMSO; compound remains stable for several months at –20°C when protected from light and moisture (APExBIO).

For a practical, protocol-driven perspective, see "SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Translational Research", which details stepwise in vitro and in vivo methodologies. This article expands on those protocols by integrating the latest mechanistic and immunometabolic findings.

Applications, Limits & Misconceptions

SU5416 (Semaxanib) is widely used in:

• Angiogenesis inhibition assays: In vitro tube formation, migration, and proliferation studies in endothelial cells.
• Tumor vascularization and growth models: In vivo xenograft experiments for anti-angiogenic and anti-tumor efficacy.
• Immune modulation research: Modeling IDO induction, Treg/Th17 balance, and transplant tolerance through AHR activation.
• Pulmonary hypertension and vascular remodeling: Investigating hypoxia and BCKA-HIF1α pathway cross-talk with VEGFR2 signaling (Xiao et al., 2024).

Common Pitfalls or Misconceptions

• SU5416 does not inhibit VEGFR1 or VEGFR3 with comparable potency; its selectivity is highest for VEGFR2 (Flk-1/KDR).
• The compound is insoluble in water and ethanol; improper solvent use leads to precipitation and assay variability.
• SU5416 is not suitable for oral dosing in animal models due to poor bioavailability; intraperitoneal or intravenous routes are required.
• It is not a cytotoxic agent per se; anti-tumor effects arise from anti-angiogenic and immunomodulatory mechanisms.
• SU5416 should not be used as a pan-kinase inhibitor; its off-target activity is limited but not negligible at high concentrations.

For advanced mechanistic insights and emerging metabolic regulatory roles, see "SU5416 (Semaxanib): Mechanistic Insights and Innovative Applications". This article updates those analyses with new data on BCKA–HIF1α cross-talk and immune modulation.

Workflow Integration & Parameters

For in vitro applications, SU5416 is typically dissolved in DMSO at a stock concentration of 10–20 mM, then diluted to working concentrations of 0.01–100 μM. Stock solutions should be aliquoted and stored at –20°C, protected from light. For in vivo studies, SU5416 is administered intraperitoneally at 1–25 mg/kg daily; dosing volumes and vehicle composition should be optimized for each protocol. Warming to 37°C or brief sonication enhances dissolution in DMSO. Mouse xenograft models tolerate these doses without acute toxicity or mortality. Detailed troubleshooting and scenario-driven advice can be found in "Solving Lab Challenges with SU5416 (Semaxanib) VEGFR2 Inhibitor"; this article extends those solutions by integrating recent immunometabolic context and cross-disciplinary benchmarks.

Conclusion & Outlook

SU5416 (Semaxanib), supplied as SKU A3847 by APExBIO, remains a cornerstone reagent for angiogenesis and immune modulation research due to its potency, selectivity, and dual mechanism of action. Its robust performance across cell-based and animal models, coupled with well-defined workflow parameters, enables reproducible and translatable insights in cancer, vascular, and immunological studies. Ongoing research into metabolic and hypoxic signaling cross-talk—such as the BCKA–HIF1α axis—continues to expand the utility of SU5416 in advanced preclinical models (Xiao et al., 2024). For comprehensive product information and ordering, visit the SU5416 (Semaxanib) VEGFR2 inhibitor page.